Search filters

List of works by Thomas E. Witzig

A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

scientific article published on 12 June 2020

A BAFF-R mutation associated with non-Hodgkin lymphoma alters TRAF recruitment and reveals new insights into BAFF-R signaling.

scientific article

A genome-wide association study of marginal zone lymphoma shows association to the HLA region

scientific article

A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy

scientific article published on 23 February 2017

A phase II trial of imatinib in patients with refractory/relapsed myeloma

scientific article published on January 2006

Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

scientific article published on 5 January 2006

Acalabrutinib for mantle cell lymphoma

scientific article published on 09 April 2019

Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis

scientific article

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare

scientific article published on 13 December 2019

Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma

scientific article published on 30 August 2019

Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types

journal article published in 2015

Anthracycline treatment, cardiovascular risk factors and the cumulative incidence of cardiovascular disease in a cohort of newly diagnosed lymphoma patients from the modern treatment era

Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?

scientific article published on 28 June 2018

Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma

scientific article published on 6 April 2017

Asymptomatic immunoglobulin light chain amyloidosis (AL) at the time of diagnostic bone marrow biopsy in newly diagnosed patients with multiple myeloma and smoldering myeloma. A series of 144 cases and a review of the literature

scientific article published on 20 July 2010

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia

scientific article published on 03 April 2018

Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis

scientific article published on 01 July 2002

Bone marrow angiogenesis in multiple myeloma: effect of therapy

article

CNS relapse in patients with DLBCL treated with lenalidomide plus R-CHOP (R2CHOP): analysis from two phase 2 studies.

scientific article published on 26 June 2018

Central nervous system involvement by mantle cell lymphoma

Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia

scientific article published on 01 April 2003

Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis

scientific article published on 05 September 2002

Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma

scientific article published on 16 June 2005

Citron Rho-interacting kinase silencing causes cytokinesis failure and reduces tumor growth in multiple myeloma

scientific article published on 01 April 2019

Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma

scientific article

Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma

Clinical course of patients with relapsed multiple myeloma

scientific article published in July 2004

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

scientific article published on 29 April 2009

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

scientific article published on 23 August 2005

Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial

scientific article

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma

scientific article published in November 2002

Data from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

scholarly article

Deletions of 17p13.1 and 13q14 are uncommon in Waldenström macroglobulinemia clonal cells and mostly seen at the time of disease progression

article

Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma

scientific article

Detection of extranodal and spleen involvement by FDG-PET imaging predicts adverse survival in untreated follicular lymphoma

scientific article published on 16 May 2019

Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia

scientific article published on 08 August 2017

Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.

scientific article published on 05 January 2017

Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines

scientific article

Early life sun exposure, vitamin D-related gene variants, and risk of non-Hodgkin lymphoma.

scientific article published on 28 April 2012

Effect of antibiotic use on outcomes in patients with Hodgkin lymphoma treated with immune checkpoint inhibitors

scientific article published on 06 October 2020

Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials

Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma

scientific article

Elevated Serum Lactate in Patients With Lymphoma: It Is Not Always Infection

Elevated pretreatment serum levels of interferon-inducible protein-10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients.

scientific article

Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders

scientific article

Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.

scientific article published on 18 February 2014

Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie

scientific article

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system

scientific article published on 8 December 2005

Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes

scientific article

Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region

scientific article published in October 2014

Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma

scientific article

History of autoimmune conditions and lymphoma prognosis

scientific article published on 01 August 2018

Host genetic variation in tumor necrosis factor and nuclear factor-κB pathways and overall survival in mantle cell lymphoma: A discovery and replication study

scientific article published on 15 March 2019

Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes

scientific article published on 29 August 2019

Impact of MYD88L265P mutation status on histological transformation of Waldenström Macroglobulinemia

scientific article published on 31 December 2019

Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?

Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma

scientific article published on 01 October 2019

Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma

scientific article published on 28 May 2019

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

scientific article published on 26 March 2009

Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma

scientific article

Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component

scientific article published on February 2009

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma

scientific article published on 16 May 2019

JAK2 activation promotes tumorigenesis in ALK-negative anaplastic large cell lymphoma via regulating oncogenic STAT1-PVT1 lncRNA axis

Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients

scientific article

Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial

scientific article published on 31 May 2011

Long-term analysis of phase II studies of single-agent lenalidomide in relapsed/refractory mantle cell lymphoma.

scientific article

Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (M

scientific article published on 14 June 2017

Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma

scientific article published in October 2007

Long-term results of single-agent thalidomide as initial therapy for asymptomatic (smoldering or indolent) myeloma

scientific article

Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia

scientific article

Long-term risk of myelodysplasia in melphalan-treated patients with immunoglobulin light-chain amyloidosis

scientific article published on 18 July 2008

Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma

scientific article published on 09 October 2018

Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma

scientific article

MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.

scientific article published on 28 October 2017

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines

scientific article published on December 2009

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

scientific article published on April 2013

Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma

scientific article published on August 2006

Methods for estimation of bone marrow plasma cell involvement in myeloma: Predictive value for response and survival in patients undergoing autologous stem cell transplantation

article

Microbial dysbiosis is associated with aggressive histology and adverse clinical outcome in B-cell non-Hodgkin lymphoma

Multicentric Castleman disease – a single center experience of treatment with a focus on autologous stem cell transplantation

Myc matters in HIV-associated lymphoma

scientific article published on 01 September 2020

Natural history of thromboembolism in AL amyloidosis

scientific article

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

scientific article published in October 2007

Oncolytic measles virus targets high CD46 expression on multiple myeloma cells

scientific article published in June 2006

Outcomes and treatments of patients with immunoglobulin light chain amyloidosis who progress or relapse postautologous stem cell transplant

scientific article published on 2 March 2014

Outcomes of patients with POEMS syndrome treated initially with radiation

scientific article

PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design

POEMS syndrome: definitions and long-term outcome

scientific article

Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia

scientific article published on 02 March 2009

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

scientific article

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

scientific article

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis

scientific article published in December 2003

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia

scientific article published on 02 October 2018

Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: a clinic-based case-control study

scientific article

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia

scientific article published on 12 October 2018

Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance

article

Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia

scientific article

Prognostic value of angiogenesis in solitary bone plasmacytoma

scientific article published on 17 October 2002

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

scientific article published on 25 March 2004

Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia

scientific article

Prospective evaluation of high-dose methotrexate pharmacokinetics in adult patients with lymphoma using novel determinants of kidney function

Proteomic Analysis of Waldenstrom Macroglobulinemia

article

RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis

scientific article published on 18 May 2021

ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma

scientific article published on 18 April 2016

Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib

scientific article published on 4 October 2016

Relationship between BCL2 mutations and follicular lymphoma outcome in the chemoimmunotherapy era

Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma

scientific article published in January 2003

Review of 1027 patients with newly diagnosed multiple myeloma

scientific article

Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018

scientific article published on 05 December 2018

Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis

scientific article published in September 2004

Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab era

scientific article

Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study

scientific article published on 22 January 2004

Supplemental Tables 1-9 from A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

Systemic amyloidosis associated with chronic lymphocytic leukemia/small lymphocytic lymphoma

scientific article published on 19 March 2013

Targeting NF-kappaB in Waldenstrom macroglobulinemia

scientific article

Targeting apoptosis pathways in cancer therapy

scientific article published on 01 May 2005

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma

scientific article published on 17 May 2019

Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL

scientific article published on 05 March 2020

Testicular FDG-PET/CT Uptake Threshold in Aggressive Lymphomas

scientific article published on 18 December 2020

The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis

scientific article

The association of physical activity before and after lymphoma diagnosis with survival outcomes

scientific article published on 17 October 2018

The effect of CRM1 inhibition on human non-Hodgkin lymphoma cells

scientific article published on 26 February 2019

The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma.

scientific article published on 28 April 2015

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome

scientific article published on 31 August 2011

Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia

scientific article published on 15 October 2020

Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement

scientific article published on March 2007

Trends and outcomes of modern staging of solitary plasmacytoma of bone

scientific article published on 2 May 2012

Urinary albumin excretion patterns of patients with cast nephropathy and other monoclonal gammopathy-related kidney diseases

scientific article

Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma.

scientific article

Paulina is supported by:

About Paulina

Help